Skip to main content
. 2024 Dec 30;25:447. doi: 10.1186/s12931-024-03073-w

Fig. 4.

Fig. 4

Crude proportions of maintenance therapies in Dutch primary care (2010–2021) from the PHARMO data network for females by age group. LABA (long-acting beta-agonist), LAMA (long-acting muscarinic antagonist), LABA-LAMA (combination of LABA and LAMA), LABA-ICS (combination of LABA and inhaled corticosteroids), LABA-LAMA-ICS (combination of LABA, LAMA, and ICS). Shaded areas represent 95% confidence intervals